Skip to main content
. 2017 Sep 1;7(9):e600. doi: 10.1038/bcj.2017.83

Figure 1.

Figure 1

Kaplan–Meier overall (n=1181) and progression-free survival (n=660) estimates for patients with newly diagnosed multiple myeloma stratified by the number of cytogenetic high-risk abnormalities (HRA): (a,c) established HRA only, (b,d) considering monosomy 13 as an additional HRA.